In-vivo and ex-vivo tests for culprit drugs identification in severe cutaneous adverse drugs reactions.
P SittiwattanawongK KantikosumK CharoenchaipiyakulS PootongkamPravit AsawanondaS J KerrP ThantiworasitP SodsaiN HirankarnJ KlaewsongkramPawinee RerknimitrPublished in: The Journal of dermatology (2024)
Drug causality assessment in severe cutaneous adverse reactions (SCARs) remains challenging. We investigated the usefulness of in-vivo drug patch tests (PT), ex-vivo interferon (IFN)-γ enzyme-linked immunospot (ELISpot) assay, and lymphocyte transformation test (LTT) in 30 SCARs patients within the past 36 months. Drug PT yielded a 20% positivity rate (n = 6), while IFN-γ ELISpot and LTT showed positive rates of 56.67% (n = 17) and 41.38% (n = 12), respectively. Combining the three tests resulted in an overall positive rate of 66.67% (n = 20) of cases. IFN-γ ELISpot offered additional positivity, especially with oxypurinol. Employing a combined diagnostic approach may enhance the chances of obtaining a positive result.
Keyphrases
- adverse drug
- dendritic cells
- drug induced
- immune response
- end stage renal disease
- ejection fraction
- newly diagnosed
- early onset
- chronic kidney disease
- peritoneal dialysis
- high throughput
- prognostic factors
- platelet rich plasma
- emergency department
- patient reported outcomes
- peripheral blood
- bioinformatics analysis
- patient reported